|Bid||19.08 x 800|
|Ask||19.40 x 1100|
|Day's Range||18.75 - 19.75|
|52 Week Range||1.61 - 73.52|
|Beta (3Y Monthly)||2.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 15, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments. Its lead program is in acute myeloid leukemia.
Bio-Path Holdings news about the company not offering additional shares of its stock has BPTH up on Monday.Source: Shutterstock Bio-Path Holdings (NASDAQ:BPTH) was planning to sell an additional 712,910 shares of BPTH stock to investors. It was pricing these shares at $25.95. However, the company's stock has been trading below that price recently. It closed on Friday at $15.65.If this new bit of Bio-Path Holdings news hadn't come about, the company would have been increasing its outstanding share amount by 28%. The company's total amount of outstanding shares was last recorded at 2.51 million as of March, 15, 2019, reports MarketWatch.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt's possible that the withdrawal of the BPTH stock offering is an attempt to increase the price of its shares. The goal may be to get shares of BPTH up above the offer price of $25.95 before moving forward again with plans to increase its outstanding shares, Seeking Alpha notes.BPTH stock was up 39% as of Monday morning and is up 311% since the start of the year. However, it's worth noting that Bio-Path Holdings saw a reverse stock split of 1 for 20 in late January. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? The stock also reached a peak of $73.52 on March 7 following positive data from a clinical trial. Despite this, it quickly fell back down to lower levels in the next couple of days. Even with this decline, it is was still sitting above its price prior to the data from the clinical trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today appeared first on InvestorPlace.
Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering. Volume was 4.3 million shares, already more than half the full-day average of about 5.7 million shares. The company said in a filing late Friday that it submitted its request for withdrawal because it "elected to not pursue the sale of securities," and confirms that no securities were sold or will be sold. On March 12, the company said it had agreed with several institutional investors to sell 712,910 shares of common stock for $25.95 each. That would have represented a 28% increase to the 2.51 million shares outstanding as of March 15. On Jan. 18, the company effected a 1-for-20 reverse stock split. The stock has run up nearly 7-fold year to date (563%), while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has climbed 15.6%.
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that data from pre-clinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer (NSCLC) and acute myelogenous leukemia (AML) were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2019 today in Atlanta, GA. The poster, entitled “BP1003, a Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor,” was presented by Ana Tari Ashizawa, Ph.D., Vice President of Research and Development at Bio-Path.
With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2018 and provided an update on recent corporate developments. “Throughout 2018, we made great progress in pursuit of our mission of bringing innovative new RNAi nanoparticle therapeutics to cancer patients with high unmet medical need,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “This progress was highlighted by the recent updated interim analysis of our Phase 2 trial of prexigebersen in acute myeloid leukemia (AML). Of the 17 evaluable patients, 65% had a response, including 29% who achieved a complete response, one of which achieved a morphologic leukemia free state.
NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 20, 2019 at 8:30 ...
HOUSTON, March 15, 2019 -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.
Bio-Path Holdings, Inc. (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced offering. In a registered direct offering, Bio-Path issued and sold 712,910 shares of its common stock for a price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements with several healthcare focused institutional investors for the issuance and sale in a registered direct offering of 712,910 shares of its common stock, at a purchase price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
That’s quite a headline, but let me ward off anyone looking for a get rich quick scheme or skeptics who hate-clicked this article. I made $8,500 on Bio-Path Holdings, Inc. (NASDAQ: BPTH ) over the course ...
The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few sub-sectors have benefited more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.
Shares of Bio-Path Holdings Inc. shot up another 130% on Thursday morning, one day after the company announced an update to its Phase 2 trial data on prexigebersen, a potential therapy for patients with acute myeloid leukemia (AML). The tiny biotech was the most heavily traded stock on the Nasdaq on Wednesday afternoon, with shares rocketing 160%. The trial enrolled 17 patients and looked at the safety and efficacy of prexigebersen combined with low-dose cytarabine compared with just low-dose cytarabine alone. Low-dose cytarabine is currently standard of care for patients who can't or do not want to be treated with more intensive chemotherapy. The company said the latest results showed that the rate of patients achieving complete remission (including those with incomplete platelet recovery and those with incomplete hematologic recovery) was 29%. The rate of complete remission for low-dose cytarabine alone is 7-13%, the company said. Bio-Path had already released positive trial results last year, and Wednesday's results were an update to that trial data. The company also noted that 68% of the patients were secondary acute myeloid leukemia patients, a particularly difficult class to treat, something not disclosed previously. Bio-Path added that it saw an opportunity for its drug BP1002 based on the recent FDA approval of venetoclax as a combination treatment for patients with AML and chronic lymphocytic leukemia. Venetoclax was developed and marketed by AbbVie and Roche Holding Ltd subsidiary Genentech. BP1002 targets the same protein as venetoclax but via a different pathway. Bio-Path thinks BP1002 could provide an alternative for patients who have relapsed while on venetoclax. Shares of Bio-Path have gained 379% in the past three months, while the S&P 500 has gained 4.4%.
NEW YORK, NY / ACCESSWIRE / March 6, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Bio-Path Holdings, Inc. (BPTH), a company that develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Bio-Path announced a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound's clinical development moving forward toward registration.
HENDERSON, NV / ACCESSWIRE / March 6, 2019 / Cannabis research firm, ArcView, sees North American legal pot sales reaching $22 billion by 2021 and $57 billion worldwide by 2027. So, it's little surprise ...
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound’s clinical development moving forward toward registration. The open-label Phase 2 study in Stage 1 evaluated the efficacy and safety of prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy. The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than would be expected with LDAC alone in a de novo patient population. Subsequently, Stage 2 of the study added a second cohort that is evaluating the efficacy and safety of prexigebersen in conjunction with Decitabine in addition to the cohort evaluating prexigebersen in conjunction with LDAC.
Peter Nielsen became the CEO of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similarRead More...
HOUSTON, Feb. 28, 2019 -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.
DALLAS, TX / ACCESSWIRE / January 24, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH): The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20Update%20JAN%202019%20Final%20v3.pdf ...
Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes. The shares of common stock offered in the registered direct offering (but not the warrants or the shares of common stock underlying the warrants) were offered and sold by Bio-Path pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-215205), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 9, 2017. The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.
The warrants will have an exercise price of $2.65 per share and exercise period commencing immediately upon issuance and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.
As a result of the reverse stock split, every 20 shares of common stock issued and outstanding were consolidated into one issued and outstanding share. The reverse stock split reduced the Company’s issued and outstanding shares of common stock from approximately 22.2 million to approximately 1.1 million. In addition, proportionate adjustments will be made to the exercise prices of the Company's outstanding stock options and warrants and to the number of shares issued and issuable under the Company's existing stock incentive plans.
Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing and funding of its previously announced underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes. A shelf registration statement on Form S-3 (Registration No. 333-215205) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 9, 2017.